Role of integrated hematological biomarkers of systemic inflammation in assessing the effectiveness of anticytokine therapy in patients with psoriasis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Integrated hematological indices are accessible, cost-effective, and objective parameters for monitoring psoriatic inflammation both in everyday clinical practice and scientific research.

Aim: The work aimed to study the effect of anticytokine therapy with an IL-17A inhibitor on NLR, PLR, MLR, SII, and SIRI indices in patients with psoriasis of varying severity.

Methods: All patients enrolled in the study had systemic inflammation indices (SIRI, MLR, NLR, SII, PLR, and AISI) calculated before treatment and 6 months after therapy with the IL-17A inhibitor (netakimab). The Psoriasis Area and Severity Index (PASI) was used to assess lesion area and severity of skin involvement.

Results: The main group included 77 patients with psoriasis: 33 women (42.9%) and 44 men (57.1%), mean age 41.3 ± 13.4 years, mean PASI 10.8 (3.2; 15.3). Of these, 58 patients (75.4%) had only cutaneous manifestations, and 19 (24.6%) had psoriatic arthritis. In accordance with the clinical guidelines of the Ministry of Health of the Russian Federation for the treatment of patients with psoriasis and psoriatic arthritis, a subgroup of patients receiving IL-17A inhibitor therapy was identified. Subgroup 1 included 20 patients with moderate-to-severe psoriasis, and subgroup 2 included 19 patients with psoriatic arthritis. The total observation period was 10 months. No adverse reactions or complications were observed. Almost complete skin clearance (PASI 75) was observed in all patients of the study group 6 months after initiation of therapy. Different diagnostic trends were observed during treatment with netakimab when analyzing SIRI, MLR, NLR, SII, PLR, and AISI in patients of both subgroups. In patients with psoriatic arthritis, MLR, NLR, and PLR indices showed no statistically significant changes during the treatment. SIRI demonstrated significant changes in both subgroups, whereas AISI was significant only in patients with moderate-to-severe psoriasis. The systemic inflammation index SII proved to be less sensitive and demonstrated changes only in patients with skin manifestations of psoriasis (p = 0.030).

Conclusion: Integrated hematological indices of systemic inflammation are promising tools for evaluating the effectiveness of anticytokine therapy in patients with severe psoriasis. NLR, MLR, SII, and AISI can be applied to evaluate the decrease in systemic inflammation exclusively during therapy in patients with cutaneous manifestations of psoriasis, whereas SIRI proved to be effective in both patients with cutaneous psoriasis and those with psoriatic arthritis.

Full Text

Restricted Access

About the authors

Nadezhda V. Batkaeva

Peoples' Friendship University of Russia

Author for correspondence.
Email: nbatkaeva.derm@yandex.ru
ORCID iD: 0000-0002-8350-5842
SPIN-code: 5884-1750

MD, Cand. Sci. (Medicine), Assistant Professor

Russian Federation, 6 Miklukho-Maklaya st, Moscow, 117198

Olga Yu. Olisova

The First Sechenov Moscow State Medical University (Sechenov University)

Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
SPIN-code: 2500-7989

MD, Dr. Sci. (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences

Russian Federation, Moscow

References

  1. Smirnova IO, Zhelonkin AR, Khazhomiya KD, et al. Pathogenesis and treatment of scalp psoriasis ― facts, hypotheses, prospects. Effective pharmacotherapy. 2023;19(19):56–62. doi: 10.33978/2307-3586-2023-19-19-56-62 EDN: WMFSBN
  2. Olisova OYu, Kochergin NG, Yazkova OS, Brezhneva AA. Phototherapy and biological for psoriasis: advantages and disadvantages. Effective pharmacotherapy. 2024;20(28):68–77. doi: 10.33978/2307-3586-2024-20-28-68-77 EDN: DCHTTZ
  3. Mondal S, Guha S, Saha A, et al. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic plaque psoriasis. Indian J Dermatol. 2022;67(4):477. doi: 10.4103/ijd.ijd_935_21
  4. Kommoss KS, Bieler T, Ringen J, et al. A simple tool for evaluation of inflammation in psoriasis: neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as markers in psoriasis patients and related murine models of psoriasis-like skin disease. J Mol Med (Berl). 2024;102(2):247–255. doi: 10.1007/s00109-023-02406-4
  5. Kulakli S, Oguz ID, Aksan B. Could blood cell-based inflammatory markers be used to monitor response to biologic therapy in psoriasis? Sisli Etfal Hastan Tip Bul. 2023;57(4):536–542. doi: 10.14744/SEMB.2023.43569
  6. Andersen CS, Kvist-Hansen A, Siewertsen M, et al. Blood cell biomarkers of inflammation and cytokine levels as predictors of response to biologics in patients with psoriasis. Int J Mol Sci. 2023;24(7):6111. doi: 10.3390/ijms24076111
  7. Adamstein NH, MacFadyen JG, Rose LM, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J. 2021;42(9):896–903. doi: 10.1093/eurheartj/ehaa1034
  8. Albayrak H. Neutrophil-to-lymphocyte ratio, neutrophil-to-monocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index in psoriasis patients: response to treatment with biological drugs. J Clin Med. 2023;12(17):5452. doi: 10.3390/jcm12175452
  9. Esen M. The effect of IL17 and IL23 inhibitors on hematological parameters and C-reactive protein in psoriasis patients. Cutan Ocul Toxicol. 2024;43(1):38–45. doi: 10.1080/15569527.2023.2275020
  10. Clinical recommendations. Psoriasis. 2023-2024-2025 (02/10/2023). Approved by the Ministry of Health of the Russian Federation. (In Russ.) Available from: http://disuria.ru/_ld/12/1261_kr23L40MZ.pdf. Accessed: 15.07.2025.
  11. Shvarts VA, Talibova SM, Sokolskaya MA, et al. Association of novel biomarkers of systemic inflammation with atherosclerosis and its severity. Russian Journal of Cardiology. 2024;29(8):67–74. doi: 10.15829/1560-4071-2024-6025 EDN: FIDYSH
  12. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. 2022;23(7):3636. doi: 10.3390/ijms23073636
  13. Lebedeva OK, Ermakov AI, Gaikovaya LB, Kukharchick GA. Monocytic and lymphocytic inflammatory reaction during myocardial infarction complicated with acute heart failure in patients with type 2 diabetes mellitus. Translational Medicine. 2021;8(4):5–17. doi: 10.18705/2311-4495-2021-8-4-5-17 EDN: JNWGWF
  14. Annen S, Horiguchi G, Teramukai S, et al. Association of transition of laboratory markers with transition of disease activity in psoriasis patients treated with biologics. J Nippon Med Sch. 2022;89(6):587–593. doi: 10.1272/jnms.JNMS.2022_89-613
  15. Morariu SH, Cotoi OS, Tiucă OM, et al. Blood-count-derived inflammatory markers as predictors of response to biologics and small-molecule inhibitors in psoriasis: a multicenter study. J Clin Med. 2024;13(14):3992. doi: 10.3390/jcm13143992
  16. Demirel Öğüt N, Ayanoğlu MA, Koç Yıldırım S, et al. Are IL-17 inhibitors superior to IL-23 inhibitors in reducing systemic inflammation in moderate-to-severe plaque psoriasis? A retrospective cohort study. Arch Dermatol Res. 2025;317(1):232. doi: 10.1007/s00403-024-03768-6

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Distribution of patients (n=77) depending on the age, %.

Download (78KB)
Indexing metadata
3. Fig. 2. Distribution of patients in study subgroups by sex, (n=77). Пс, patients with only skin manifestations of psoriasis (group 1); ПсА, patients with psoriatic arthritis (group 2).

Download (88KB)
Indexing metadata
4. Fig. 3. Distribution of patients depending on the severity of the skin process, (n=77). Пс, patients with only skin manifestations of psoriasis (group 1); ПсА, patients with psoriatic arthritis (group 2).

Download (105KB)
Indexing metadata
5. Fig. 4. Dynamics of neutrophils lymphocytes ratio (NLR) in patients with severe forms of psoriasis and psoriatic arthritis during treatment with netakimab, (n=49). Пс, patients with only skin manifestations of psoriasis (group 1); ПсА, patients with psoriatic arthritis (group 2).

Download (95KB)
Indexing metadata
6. Fig. 5. Dynamics of platelets lymphocytes ratio (PLR) in patients with severe forms of psoriasis and psoriatic arthritis during treatment with netakimab, (n=49). Пс, patients with only skin manifestations of psoriasis (group 1); ПсА, patients with psoriatic arthritis (group 2).

Download (102KB)
Indexing metadata
7. Fig. 6. Dynamics of monocytes lymphocytes ratio (MLR) in patients with severe forms of psoriasis and psoriatic arthritis during treatment with netakimab, (n=49). Пс, patients with only skin manifestations of psoriasis (group 1); ПсА, patients with psoriatic arthritis (group 2).

Download (100KB)
Indexing metadata
8. Fig. 7. Dynamics of Systemic Inflammation Index (SII) in patients with severe psoriasis and psoriatic arthritis during treatment with netakimab, (n=49). Пс, patients with only skin manifestations of psoriasis (group 1); ПсА, patients with psoriatic arthritis (group 2).

Download (115KB)
Indexing metadata
9. Fig. 8. Dynamics of Systemic Inflammation Response Index (SIRI) in patients with severe psoriasis and psoriatic arthritis during treatment with netakimab, (n=49). Пс, patients with only skin manifestations of psoriasis (group 1); ПсА, patients with psoriatic arthritis (group 2).

Download (119KB)
Indexing metadata
10. Fig. 9. Dynamics of AISI (Aggregate Inflammation Systemic Index) in patients with severe psoriasis and psoriatic arthritis during treatment with netakimab, (n=49). Пс, patients with only skin manifestations of psoriasis (group 1); ПсА, patients with psoriatic arthritis (group 2).

Download (119KB)
Indexing metadata

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.